Renin-angiotensin system inhibitors in the COVID-19 pandemic: consequences of antihypertensive drugs

Eur Heart J. 2020 Jun 7;41(22):2067-2069. doi: 10.1093/eurheartj/ehaa487.

Authors

Luis M Ruilope^{1

2

3}, Juan Tamargo⁴, Gema Ruiz-Hurtado^{1

2}

Affiliations

¹ Cardiorenal Translational Laboratory & Hypertension Unit, Institute of Research i+12, Hospital Universitario 12 de Octubre, Madrid, Spain.
² CIBER-CV, Hospital Universitario 12 de Octubre, Madrid, Spain.
³ Faculty of Sport Sciences, European University of Madrid, Madrid, Spain.
⁴ Department of Pharmacology and Toxicology, School of Medicine, Instituto De Investigación Sanitaria Gregorio Marañón, Universidad Complutense, Madrid, Spain.

No abstract available

Publication types

Comment

MeSH terms

Antihypertensive Agents
Betacoronavirus
COVID-19
Coronavirus Infections
Humans
Hypertension*
Pandemics
Pneumonia, Viral
Renin-Angiotensin System / drug effects*
Retrospective Studies
SARS-CoV-2

Substances

Antihypertensive Agents